Latest Breaking News On - Sellas life sciences group - Page 1 : vimarsana.com

SELLAS Life Sciences Group, Inc (NASDAQ:SLS) Sees Large Drop in Short Interest

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 3,120,000 shares, a decrease of 19.6% from the January 15th total of 3,880,000 shares. Based on an average daily trading volume, of 990,800 shares, […]

United statesLife sciences group tradingLife sciences group incSellas life sciences group incLife sciences group dailyWells fargo companyLife sciences groupVirtu financialEquitable holdings incCantor fitzgeraldNorthern trust corpSciences groupGet free reportStreet corpTrust corpSciences group daily

SELLAS Life Sciences Shares Fall Premarket on Stock Offering Plans

By Colin Kellaher Shares of SELLAS Life Sciences Group tumbled nearly 30% in premarket trading Thursday after the clinical-stage biopharmaceutical company.

New yorkUnited statesColin kellaherLife sciences groupSciences groupArticle normalBiotechnology servicesHealthcare life sciencesFinancial performanceShare price movement disruptionsCorporate fundingShare capitalOwnership changesAcquisitions mergers shareholdingsCorporate actionsCorporate industrial news

SELLAS Life Sciences Announces Pricing of $9 0 Million

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical.

Memorial sloan kettering cancer centerNew yorkUnited statesBruce mackleExchange commissionLife sciences group incLifesci advisorsA gp alliance global partnersGenfleet therapeutics shanghai incSciences groupAlliance global partnersGenfleet therapeuticsAnnual reportSci advisorsNasdaq slsSellas life sciences group

GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies

A new research paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, "The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies."

Qiang luLili tangFubo xieSiyuan leFusheng zhouJinmin renDragan cicicGenfleet therapeutics incSellas life sciences groupJiong lanGenfleet therapeuticsCell cycleN vivoProtein expression

Potent and highly selective CDK9 inhibitor for treatment of hematologic malignancies

Potent and highly selective CDK9 inhibitor for treatment of hematologic malignancies
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Fusheng zhouGenfleet therapeutics incSellas life sciences groupGenfleet therapeutics